A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Prof. Timothy Vollmer, MD
University of Colorado, Denver
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
144 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Teva Investigational Site 5914
Pleven, Bulgaria
- Teva Investigational Site 5915
Pleven, Bulgaria
- Teva Investigational Site 5917
Plovdiv, Bulgaria
- Teva Investigational Site 4212
Rousse, Bulgaria
- Teva Investigational Site 5916
Shumen, Bulgaria
- Teva Investigational Site 5906
Sofia, Bulgaria
- Teva Investigational Site 5907
Sofia, Bulgaria
- Teva Investigational Site 5908
Sofia, Bulgaria
- Teva Investigational Site 5909
Sofia, Bulgaria
- Teva Investigational Site 5910
Sofia, Bulgaria
- Teva Investigational Site 5911
Sofia, Bulgaria
- Teva Investigational Site 5912
Sofia, Bulgaria
- Teva Investigational Site 5919
Sofia, Bulgaria
- Teva Investigational Site 5920
Sofia, Bulgaria
- Teva Investigational Site 5918
Stara Zagora, Bulgaria
- Teva Investigational Site 5913
Varna, Bulgaria
- Teva Investigational Site 4211
Veliko Tarnovo, Bulgaria
- Teva Investigational Site 6003
Osijek, Croatia
- Teva Investigational Site 6005
Varaždin, Croatia
- Teva Investigational Site 6001
Zagreb, Croatia
- Teva Investigational Site 6002
Zagreb, Croatia
- Teva Investigational Site 6006
Zagreb, Croatia
- Teva Investigational Site 5419
Olomouc, Czechia
- Teva Investigational Site 5418
Prague, Czechia
- Teva Investigational Site 5420
Praha 5- Motol, Czechia
- Teva Investigational Site 5421
Teplice, Czechia
- Teva Investigational Site 5508
Kohtla-Järve, Estonia
- Teva Investigational Site 5507
Tallinn, Estonia
- Teva Investigational Site 5509
Tartu, Estonia
- Teva Investigational Site 8102
Tbilisi, Georgia
- Teva Investigational Site 8103
Tbilisi, Georgia
- Teva Investigational Site 8104
Tbilisi, Georgia
- Teva Investigational Site 6402
Berlin, Germany
- Teva Investigational Site 6703
Berlin, Germany
- Teva Investigational Site 6400
Ulm, Germany
- Teva Investigational Site 8041
Jerusalem, Israel
- Teva Investigational Site 8040
Ramat Gan, Israel
- Teva Investigational Site 3056
Bologna, Italy
- Teva Investigational Site 3053
Cefalù, Italy
- Teva Investigational Site 3054
Chieti, Italy
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 May 2010
- Primary completion
- 30 Jun 2017
- Completion
- 30 Jun 2017
- Last update posted
- 9 Dec 2021
- Registered enrollment
- 1,047
- Registry id
- NCT01047319
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.